These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 27653758)

  • 1. Apixaban: A Review in Venous Thromboembolism.
    Greig SL; Garnock-Jones KP
    Drugs; 2016 Oct; 76(15):1493-1504. PubMed ID: 27653758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical presentation and course of bleeding events in patients with venous thromboembolism, treated with apixaban or enoxaparin and warfarin. Results from the AMPLIFY trial.
    Bleker SM; Cohen AT; Büller HR; Agnelli G; Gallus AS; Raskob GE; Weitz JI; Curto M; Sisson M; Middeldorp S
    Thromb Haemost; 2016 Nov; 116(6):1159-1164. PubMed ID: 27583312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and economic benefits of extended treatment with apixaban for the treatment and prevention of recurrent venous thromboembolism in Canada.
    Quon P; Le HH; Raymond V; Mtibaa M; Moshyk A
    J Med Econ; 2016 Jun; 19(6):557-67. PubMed ID: 26761644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.
    Rollins BM; Silva MA; Donovan JL; Kanaan AO
    Clin Ther; 2014 Oct; 36(10):1454-64.e3. PubMed ID: 25092394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial.
    Agnelli G; Buller HR; Cohen A; Gallus AS; Lee TC; Pak R; Raskob GE; Weitz JI; Yamabe T
    J Thromb Haemost; 2015 Dec; 13(12):2187-91. PubMed ID: 26407753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bleeding and recurrent VTE with apixaban vs warfarin as outpatient treatment: time-course and subgroup analyses.
    Weycker D; Wygant GD; Guo JD; Lee T; Luo X; Rosenblatt L; Mardekian J; Atwood M; Hanau A; Cohen AT
    Blood Adv; 2020 Jan; 4(2):432-439. PubMed ID: 31990332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY Trial.
    Cohen AT; Agnelli G; Buller HR; Gallus A; Raskob GE; Sanders P; Thompson J; Weitz JI
    Thromb Haemost; 2019 Mar; 119(3):461-466. PubMed ID: 30650446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Clinical and Economic Outcomes Associated with Warfarin Versus Apixaban in the Treatment of Patients with Venous Thromboembolism in a Large U.S. Commercial Claims Database.
    Guo JD; Rajpura J; Hlavacek P; Keshishian A; Sah J; Delinger R; Mu Q; Mardekian J; Russ C; Okano GJ; Rosenblatt L
    J Manag Care Spec Pharm; 2020 Aug; 26(8):1017-1026. PubMed ID: 32452277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and Safety of Apixaban versus Warfarin as Outpatient Treatment of Venous Thromboembolism in U.S. Clinical Practice.
    Weycker D; Li X; Wygant GD; Lee T; Hamilton M; Luo X; Vo L; Mardekian J; Pan X; Burns L; Atwood M; Hanau A; Cohen AT
    Thromb Haemost; 2018 Nov; 118(11):1951-1961. PubMed ID: 30357780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abnormal vaginal bleeding in women with venous thromboembolism treated with apixaban or warfarin.
    Brekelmans MP; Scheres LJ; Bleker SM; Hutten BA; Timmermans A; Büller HR; Middeldorp S
    Thromb Haemost; 2017 Apr; 117(4):809-815. PubMed ID: 28180233
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study.
    Alzghari SK; Seago SE; Garza JE; Hashimie YF; Baty KA; Evans MF; Shaver C; Herrington JD
    J Oncol Pharm Pract; 2018 Oct; 24(7):494-500. PubMed ID: 28714376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral apixaban for the treatment of acute venous thromboembolism.
    Agnelli G; Buller HR; Cohen A; Curto M; Gallus AS; Johnson M; Masiukiewicz U; Pak R; Thompson J; Raskob GE; Weitz JI;
    N Engl J Med; 2013 Aug; 369(9):799-808. PubMed ID: 23808982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apixaban for the Treatment of Japanese Subjects With Acute Venous Thromboembolism (AMPLIFY-J Study).
    Nakamura M; Nishikawa M; Komuro I; Kitajima I; Uetsuka Y; Yamagami T; Minamiguchi H; Yoshimatsu R; Tanabe K; Matsuoka N; Kanmuri K; Ogawa H
    Circ J; 2015; 79(6):1230-6. PubMed ID: 25912695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism.
    Wysokinski WE; Houghton DE; Casanegra AI; Vlazny DT; Bott-Kitslaar DM; Froehling DA; Hodge DO; Peterson LG; Mcbane RD
    Am J Hematol; 2019 Nov; 94(11):1185-1192. PubMed ID: 31378995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Apixaban Reduces Hospitalizations in Patients With Venous Thromboembolism: An Analysis of the Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy (AMPLIFY) Trial.
    Liu X; Johnson M; Mardekian J; Phatak H; Thompson J; Cohen AT
    J Am Heart Assoc; 2015 Dec; 4(12):. PubMed ID: 26627879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement.
    Lassen MR; Davidson BL; Gallus A; Pineo G; Ansell J; Deitchman D
    J Thromb Haemost; 2007 Dec; 5(12):2368-75. PubMed ID: 17868430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety, effectiveness, and health care cost comparisons among elderly patients with venous thromboembolism prescribed warfarin or apixaban in the United States Medicare population.
    Hlavacek P; Guo JD; Rosenblatt L; Keshishian A; Russ C; Mardekian J; Ferri M; Poretta T; Yuce H; McBane R
    Curr Med Res Opin; 2019 Dec; 35(12):2043-2051. PubMed ID: 31387467
    [No Abstract]   [Full Text] [Related]  

  • 18. Effectiveness and Safety of Apixaban, Low-Molecular-Weight Heparin, and Warfarin among Venous Thromboembolism Patients with Active Cancer: A U.S. Claims Data Analysis.
    Cohen A; Keshishian A; Lee T; Wygant G; Rosenblatt L; Hlavacek P; Mardekian J; Wiederkehr D; Sah J; Luo X
    Thromb Haemost; 2021 Mar; 121(3):383-395. PubMed ID: 33171521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early time courses of recurrent thromboembolism and bleeding during apixaban or enoxaparin/warfarin therapy. A sub-analysis of the AMPLIFY trial.
    Raskob GE; Gallus AS; Sanders P; Thompson JR; Agnelli G; Buller HR; Cohen AT; Ramacciotti E; Weitz JI
    Thromb Haemost; 2016 Apr; 115(4):809-16. PubMed ID: 26661288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety ad efficacy of direct oral anticoagulants for extended treatment of venous thromboembolism.
    Imberti D; Pomero F; Benedetti R; Fenoglio L
    Intern Emerg Med; 2016 Oct; 11(7):895-900. PubMed ID: 27550399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.